BMS-986442 + nivolumab

BMS-986442 + nivolumab is an investigational **combination therapy** composed of BMS-986442—a novel bispecific monoclonal antibody that targets TIGIT and CD96—and nivolumab, an approved PD-1 immune checkpoint inhibitor. BMS-986442 works by blocking both TIGIT and CD96, aiming to activate immune cells and enhance anti-tumor responses. Nivolumab blocks PD-1, releasing a brake on immune T cells. This combination is being developed by Bristol Myers Squibb for the treatment of advanced solid tumors, including non-small cell lung cancer, in hopes of improving antitumor efficacy by simultaneously targeting multiple immune-inhibitory pathways[1][2][3][7][9].

Brand names

Opdivo (for nivolumab)BMS-986442 + nivolumab

Other names

BMS-986442 and nivolumabBMS986442 and nivolumabBMS 986442 and nivolumabBMS-986442/Opdivo